New guidance provides definition for orphan device, offers alternative trial designs
New guidance from the European Commission outlines alternatives for full pre-market clinical trials for orphan devices, defined by the Commission for the first time. While the limited pre-market clinical data still must be “sufficient,” the document offers potential alternative clinical trial designs and statistical considerations. Notably, this is also the first guidance to describe the possible use of a conditional Notified Body certificate.
Fill out the form to read the full article.
Required *